News & Updates

Show Multimedia Only
Pemafibrate superior to conventional fibrates in T2DM

Pemafibrate superior to conventional fibrates in T2DM

01 Oct 2022

Treatment with pemafibrate in patients with type 2 diabetes mellitus (T2DM) yields more favourable effects on lipid profile, as well renal function, as compared with conventional fibrates, a study has found.

01 Oct 2022
Brolucizumab for neovascular age-related macular degeneration holds up in real world

Brolucizumab for neovascular age-related macular degeneration holds up in real world

30 Sep 2022

The use of brolucizumab for the treatment of patients with neovascular age-related macular degeneration (nAMD) in the real-world setting appears to be effective and safe, consistent with data from pivotal trials, as reported in a study.

30 Sep 2022